PepGen Inc. Announces Clinical Hold In The US On IND Application To Initiate Phase 1 Study Of PGN-EDODM1 For Myotonic Dystrophy Type 1 (DM1)
Portfolio Pulse from Benzinga Newsdesk
PepGen Inc. announces a clinical hold in the US on its IND application to initiate a Phase 1 study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1).
May 30, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PepGen Inc. faces a clinical hold in the US on its IND application for a Phase 1 study of PGN-EDODM1, potentially delaying the development of the drug for Myotonic Dystrophy Type 1.
The clinical hold on PepGen Inc.'s IND application for PGN-EDODM1 may result in delays in the development and potential approval of the drug for Myotonic Dystrophy Type 1. This could negatively impact the company's stock price in the short term as investors may perceive this as a setback in the company's progress.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100